Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.07.2012 | Epidemiology

Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls

verfasst von: D. B. Jeffe, M. Pérez, Y. Liu, K. K. Collins, R. L. Aft, M. Schootman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Little is known about quality-of-life (QOL) differences over time between incident ductal carcinoma in situ (DCIS) and early-stage invasive breast cancer (EIBC) cases as compared with same-aged women without breast cancer (controls). We prospectively recruited and interviewed 1,096 women [16.8 % DCIS, 33.3 % EIBC (25.7 % Stage I; and 7.6 % Stage IIA), 49.9 % controls; mean age 58; 23.7 % non-white] at mean 6.7 weeks (T1), and 6.2 (T2), 12.3 (T3), and 24.4 months (T4) after surgery (patients) or screening mammogram (controls). We tested two hypotheses: (1) DCIS patients would report lower levels of QOL compared with controls but would report similar QOL compared with EIBC patients at baseline; and (2) DCIS patients’ QOL would improve during 2-year follow-up and approach levels similar to that of controls faster than EIBC patients. We tested hypothesis 1 using separate general linear regression models for each of the eight subscales on the RAND 36-item Health Survey, controlling for variables associated with at least one subscale at T1. Both DCIS and EIBC patients reported lower QOL at T1 than controls on all subscales (each P < 0.05). We tested hypothesis 2 using generalized estimating equations to examine change in each QOL subscale over time across the three diagnostic groups adjusting for covariates. By T3, physical functioning, role limitations due to physical problems, energy/fatigue, and general health each differed significantly by diagnostic group at P < 0.05, because of larger differences between EIBC patients and controls; but DCIS patients no longer differed significantly from controls on any of the QOL subscales. At T4, EIBC patients still reported worse physical functioning (P = 0.0001) and general health (P = 0.0017) than controls, possibly because of lingering treatment effects. DCIS patients’ QOL was similar to that of controls two years after diagnosis, but some aspects of EIBC patients’ QOL remained lower.
Literatur
1.
Zurück zum Zitat Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI, Consensus Conference Committee (2000) The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Breast J 6(1):4–13CrossRef Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI, Consensus Conference Committee (2000) The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Breast J 6(1):4–13CrossRef
2.
Zurück zum Zitat Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100(22):1643–1648PubMedCrossRef Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100(22):1643–1648PubMedCrossRef
3.
Zurück zum Zitat Amichetti M, Caffo O, Arcicasa M, Roncadin M, Lora O, Rigon A, Zini G, Armaroli L, Coghetto F, Zorat P, Neri S, Teodorani N (1999) Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. Breast Cancer Res Treat 54(2):109–115PubMedCrossRef Amichetti M, Caffo O, Arcicasa M, Roncadin M, Lora O, Rigon A, Zini G, Armaroli L, Coghetto F, Zorat P, Neri S, Teodorani N (1999) Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. Breast Cancer Res Treat 54(2):109–115PubMedCrossRef
4.
Zurück zum Zitat Claus EB, Petruzella S, Carter D, Kasl S (2006) Quality of life for women diagnosed with breast carcinoma in situ. J Clin Oncol 24(30):4875–4881 Claus EB, Petruzella S, Carter D, Kasl S (2006) Quality of life for women diagnosed with breast carcinoma in situ. J Clin Oncol 24(30):4875–4881
5.
Zurück zum Zitat van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556PubMedCrossRef van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556PubMedCrossRef
6.
Zurück zum Zitat Nekhlyudov L, Kroenke CH, Jung I, Holmes MD, Colditz GA (2006) Prospective changes in quality of life after ductal carcinoma-in-situ: results from the Nurses’ Health Study. J Clin Oncol 24(18):2822–2827PubMedCrossRef Nekhlyudov L, Kroenke CH, Jung I, Holmes MD, Colditz GA (2006) Prospective changes in quality of life after ductal carcinoma-in-situ: results from the Nurses’ Health Study. J Clin Oncol 24(18):2822–2827PubMedCrossRef
7.
Zurück zum Zitat Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350(14):1430–1441PubMedCrossRef Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350(14):1430–1441PubMedCrossRef
8.
Zurück zum Zitat Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party, DCIS trialists in the UK, Australia, and New Zealand (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102PubMedCrossRef Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party, DCIS trialists in the UK, Australia, and New Zealand (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102PubMedCrossRef
9.
Zurück zum Zitat Morrow M, Strom E, Bassett L, Dershaw DD, Fowble B, Harris JR, O’Malley F, Schnitt SJ, Singletary SE, Winchester DP (2002) Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52(5):256–276PubMedCrossRef Morrow M, Strom E, Bassett L, Dershaw DD, Fowble B, Harris JR, O’Malley F, Schnitt SJ, Singletary SE, Winchester DP (2002) Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52(5):256–276PubMedCrossRef
10.
Zurück zum Zitat Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, Gamagami P (1995) Ten year results comparing mastectomy to excision and radiotherapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, Gamagami P (1995) Ten year results comparing mastectomy to excision and radiotherapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef
11.
Zurück zum Zitat Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRef Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRef
12.
Zurück zum Zitat Elder E, Kennedy C, Gluch L, Carmalt H, Janu N, Joseph M, Donellan M, Molland J, Gillett D (2006) Patterns of breast cancer relapse. Eur J Surg Oncol 32:922–927PubMedCrossRef Elder E, Kennedy C, Gluch L, Carmalt H, Janu N, Joseph M, Donellan M, Molland J, Gillett D (2006) Patterns of breast cancer relapse. Eur J Surg Oncol 32:922–927PubMedCrossRef
13.
Zurück zum Zitat Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251PubMedCrossRef Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251PubMedCrossRef
14.
Zurück zum Zitat Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16(2):501–514PubMed Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16(2):501–514PubMed
15.
Zurück zum Zitat Härtl K, Engel J, Herschbach P, Reinecker H, Sommer H, Friese K (2010) Personality traits and psychosocial stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psychooncology 19(2):160–169PubMedCrossRef Härtl K, Engel J, Herschbach P, Reinecker H, Sommer H, Friese K (2010) Personality traits and psychosocial stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psychooncology 19(2):160–169PubMedCrossRef
16.
Zurück zum Zitat Trentham-Dietz A, Sprague B, Klein R, Klein B, Cruickshanks K, Fryback D, Hampton J (2008) Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat 109(2):379–387PubMedCrossRef Trentham-Dietz A, Sprague B, Klein R, Klein B, Cruickshanks K, Fryback D, Hampton J (2008) Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat 109(2):379–387PubMedCrossRef
17.
Zurück zum Zitat Michael Y, Kawachi I, Berkman L, Holmes M, Colditz G (2000) The persistent impact of breast carcinoma on functional health status. Cancer 89(11):2176–2186PubMedCrossRef Michael Y, Kawachi I, Berkman L, Holmes M, Colditz G (2000) The persistent impact of breast carcinoma on functional health status. Cancer 89(11):2176–2186PubMedCrossRef
18.
Zurück zum Zitat Leitch AM, Dodd GD, Costanza M, Linver M, Pressman P, McGinnis L, Smith RA (1997) American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Clin 47:150–153PubMedCrossRef Leitch AM, Dodd GD, Costanza M, Linver M, Pressman P, McGinnis L, Smith RA (1997) American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Clin 47:150–153PubMedCrossRef
19.
Zurück zum Zitat Carrera C, Payne S (1999) Ductal carcinoma in situ (DCIS) of the breast: the need for psychosocial research. Psychooncology 8:538–545PubMedCrossRef Carrera C, Payne S (1999) Ductal carcinoma in situ (DCIS) of the breast: the need for psychosocial research. Psychooncology 8:538–545PubMedCrossRef
20.
Zurück zum Zitat Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short Orientation–Memory–Concentration test of cognitive impairment. Am J Psychiatry 140:734–739PubMed Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short Orientation–Memory–Concentration test of cognitive impairment. Am J Psychiatry 140:734–739PubMed
21.
Zurück zum Zitat Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-item health survey 1.0. Health Econ 2:217–227PubMedCrossRef Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-item health survey 1.0. Health Econ 2:217–227PubMedCrossRef
22.
Zurück zum Zitat Stewart AL, Greenfield S, Hays R, Wells K, Rogers W, Berry S, McGlynn E, Ware J (1989) Functional status and well-being of patients with chronic conditions. JAMA 262:907–913PubMedCrossRef Stewart AL, Greenfield S, Hays R, Wells K, Rogers W, Berry S, McGlynn E, Ware J (1989) Functional status and well-being of patients with chronic conditions. JAMA 262:907–913PubMedCrossRef
23.
Zurück zum Zitat Stewart AL, Hays R, Ware J (1988) The MOS short-form general health survey: reliability and validity in a patient population. Med Care 26:724–735PubMedCrossRef Stewart AL, Hays R, Ware J (1988) The MOS short-form general health survey: reliability and validity in a patient population. Med Care 26:724–735PubMedCrossRef
24.
Zurück zum Zitat Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Med Care 30:473–483PubMedCrossRef Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Med Care 30:473–483PubMedCrossRef
25.
Zurück zum Zitat Wells KB, Stewart AL, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware JE (1989) The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 262:914–919PubMedCrossRef Wells KB, Stewart AL, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware JE (1989) The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 262:914–919PubMedCrossRef
26.
Zurück zum Zitat Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D (1999) Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15:141–155PubMedCrossRef Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D (1999) Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15:141–155PubMedCrossRef
27.
Zurück zum Zitat Hays RD, Morales LS (2001) The RAND-36 measure of health-related quality of life. Ann Med 33(5):350–357PubMedCrossRef Hays RD, Morales LS (2001) The RAND-36 measure of health-related quality of life. Ann Med 33(5):350–357PubMedCrossRef
28.
29.
Zurück zum Zitat Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34(1):73–84PubMedCrossRef Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34(1):73–84PubMedCrossRef
30.
Zurück zum Zitat Charlson ME, Pompei P, Ales K, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales K, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383PubMedCrossRef
31.
Zurück zum Zitat Perez M, Liu Y, Schootman M, Aft R, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924–937 Perez M, Liu Y, Schootman M, Aft R, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924–937
32.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) American Joint Committee on cancer staging manual, 6th edn. Springer, New York Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) American Joint Committee on cancer staging manual, 6th edn. Springer, New York
33.
Zurück zum Zitat Lauzier S, Maunsell E, Levesque P, Mondor M, Robert J, Robidoux A, Provencher L (2010) Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 120:685–691PubMedCrossRef Lauzier S, Maunsell E, Levesque P, Mondor M, Robert J, Robidoux A, Provencher L (2010) Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 120:685–691PubMedCrossRef
34.
Zurück zum Zitat Klein D, Mercier M, Abeilard E, Puyraveau M, Danzon A, Dalstein V, Pozet A, Guizard AV, Henry-Amar M, Velten M (2011) Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Res Treat 129:125–134PubMedCrossRef Klein D, Mercier M, Abeilard E, Puyraveau M, Danzon A, Dalstein V, Pozet A, Guizard AV, Henry-Amar M, Velten M (2011) Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Res Treat 129:125–134PubMedCrossRef
35.
Zurück zum Zitat Paskett E, Alfano C, Davidson M, Andersen B, Naughton M, Sherman A, Green P, Hays J (2008) Breast cancer survivors’ health-related quality of life. Cancer 113(11):3222–3230PubMedCrossRef Paskett E, Alfano C, Davidson M, Andersen B, Naughton M, Sherman A, Green P, Hays J (2008) Breast cancer survivors’ health-related quality of life. Cancer 113(11):3222–3230PubMedCrossRef
36.
Zurück zum Zitat Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KE, Fleming GF, Bittoni MA, ftCaL GB (2008) Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology 17:1108–1120PubMedCrossRef Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KE, Fleming GF, Bittoni MA, ftCaL GB (2008) Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology 17:1108–1120PubMedCrossRef
37.
Zurück zum Zitat Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) collaborators (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) collaborators (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef
38.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) (2011) SEER cancer statistics review, 1975–2008. Updated Nov 10, 2011. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2008/. Accessed 1 Feb 2012 Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) (2011) SEER cancer statistics review, 1975–2008. Updated Nov 10, 2011. National Cancer Institute, Bethesda, MD. http://​seer.​cancer.​gov/​csr/​1975_​2008/​. Accessed 1 Feb 2012
39.
Zurück zum Zitat Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96(5):376–387PubMedCrossRef Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96(5):376–387PubMedCrossRef
40.
Zurück zum Zitat Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, Saito M, Iha S, Watanabe T, Katsumata N (2011) Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 128:735–747PubMedCrossRef Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, Saito M, Iha S, Watanabe T, Katsumata N (2011) Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 128:735–747PubMedCrossRef
41.
Zurück zum Zitat Arndt V, Stegmaier C, Ziegler H, Brenner H (2008) Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol 134(12):1311–1318PubMedCrossRef Arndt V, Stegmaier C, Ziegler H, Brenner H (2008) Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol 134(12):1311–1318PubMedCrossRef
43.
Zurück zum Zitat Mokbel K (2003) Current management of ductal carcinoma in situ of the breast. Int J Clin Oncol 8:18–22PubMedCrossRef Mokbel K (2003) Current management of ductal carcinoma in situ of the breast. Int J Clin Oncol 8:18–22PubMedCrossRef
44.
45.
Zurück zum Zitat Kwan ML, Ergas IJ, Somkin CP, Quesenberry CP, Neugut AI, Hershman DL, Mandelblatt J, Pelayo MP, Timperi AW, Miles SQ, Kushi LH (2010) Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat 123(2):507–524PubMedCrossRef Kwan ML, Ergas IJ, Somkin CP, Quesenberry CP, Neugut AI, Hershman DL, Mandelblatt J, Pelayo MP, Timperi AW, Miles SQ, Kushi LH (2010) Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat 123(2):507–524PubMedCrossRef
46.
Zurück zum Zitat Ahmed RL, Prizment A, Lazovich D, Schnitz KH, Folsom AR (2008) Lymphedema and quality of life in breast cancer survivors: the Iowa Women’s Health Study. J Clin Oncol 26(35):5689–5696PubMedCrossRef Ahmed RL, Prizment A, Lazovich D, Schnitz KH, Folsom AR (2008) Lymphedema and quality of life in breast cancer survivors: the Iowa Women’s Health Study. J Clin Oncol 26(35):5689–5696PubMedCrossRef
47.
Zurück zum Zitat Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD (2004) Functional impact of breast cancer by age at diagnosis. J Clin Oncol 22(10):1849–1856PubMedCrossRef Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD (2004) Functional impact of breast cancer by age at diagnosis. J Clin Oncol 22(10):1849–1856PubMedCrossRef
48.
Zurück zum Zitat Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA (2011) The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study. J Cancer Surviv 5(1):62–72PubMedCrossRef Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA (2011) The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study. J Cancer Surviv 5(1):62–72PubMedCrossRef
49.
Zurück zum Zitat Mar Fan HG, Houédé-Tchen N, Yi Q, Chemerynsky LI, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23(31):8025–8032CrossRef Mar Fan HG, Houédé-Tchen N, Yi Q, Chemerynsky LI, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23(31):8025–8032CrossRef
50.
Zurück zum Zitat Casso D, Buist DS, Taplin S (2004) Quality of life of 5–10 year breast cancer survivors diagnosed between age 40 and 49. Health Qual Life Outcomes 2:25PubMedCrossRef Casso D, Buist DS, Taplin S (2004) Quality of life of 5–10 year breast cancer survivors diagnosed between age 40 and 49. Health Qual Life Outcomes 2:25PubMedCrossRef
51.
Zurück zum Zitat Janz NK, Mujahid MS, Hawley ST, Griggs JJ, Alderman A, Hamilton AS, Graff J, Katz SJ (2009) Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv 3(4):212–222PubMedCrossRef Janz NK, Mujahid MS, Hawley ST, Griggs JJ, Alderman A, Hamilton AS, Graff J, Katz SJ (2009) Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv 3(4):212–222PubMedCrossRef
52.
Zurück zum Zitat Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Linvingston RB, Perez EA, Mamounas EP, Womark N, Swain SM (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29(9):1110–1116PubMedCrossRef Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Linvingston RB, Perez EA, Mamounas EP, Womark N, Swain SM (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29(9):1110–1116PubMedCrossRef
53.
Zurück zum Zitat Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Sigglekow W, Kandelhardt E, Koelbl H (2009) Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care 18:500–506CrossRef Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Sigglekow W, Kandelhardt E, Koelbl H (2009) Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care 18:500–506CrossRef
54.
Zurück zum Zitat Day R (2001) Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. Ann NY Acad Sci 949:143–150PubMedCrossRef Day R (2001) Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. Ann NY Acad Sci 949:143–150PubMedCrossRef
55.
Zurück zum Zitat Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, Murray J, Macaskill EJ, McCaig F, Dixon OM, Fallowfield LJ (2011) Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 125(3):741–749PubMedCrossRef Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, Murray J, Macaskill EJ, McCaig F, Dixon OM, Fallowfield LJ (2011) Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 125(3):741–749PubMedCrossRef
56.
Zurück zum Zitat Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L (1996) Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 38:183–199PubMedCrossRef Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L (1996) Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 38:183–199PubMedCrossRef
57.
Zurück zum Zitat Dorval M, Maunsell E, Deschenes L, Brisson J, Masse B (1998) Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 16(2):487–494PubMed Dorval M, Maunsell E, Deschenes L, Brisson J, Masse B (1998) Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 16(2):487–494PubMed
58.
Zurück zum Zitat Ashing-Giwa KT, Lim JW (2011) Examining emotional outcomes among a multiethnic cohort of breast cancer survivors. Oncol Nurs Forum 38(3):279–288PubMedCrossRef Ashing-Giwa KT, Lim JW (2011) Examining emotional outcomes among a multiethnic cohort of breast cancer survivors. Oncol Nurs Forum 38(3):279–288PubMedCrossRef
59.
Zurück zum Zitat Spencer SM, Lehman JM, Wynings C, Arena P, Carver CS, Antoni MH, Derhagopian RP, Ironson G, Love N (1999) Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early-stage patients. Health Psychol 18(2):159–168PubMedCrossRef Spencer SM, Lehman JM, Wynings C, Arena P, Carver CS, Antoni MH, Derhagopian RP, Ironson G, Love N (1999) Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early-stage patients. Health Psychol 18(2):159–168PubMedCrossRef
60.
Zurück zum Zitat Culver JL, Arena PL, Antoni MH, Carver CS (2002) Coping and distress among women under treatment for early stage breast cancer: comparing African Americans, Hispanics and non-Hispanic Whites. Psychooncology 11(6):495–504PubMedCrossRef Culver JL, Arena PL, Antoni MH, Carver CS (2002) Coping and distress among women under treatment for early stage breast cancer: comparing African Americans, Hispanics and non-Hispanic Whites. Psychooncology 11(6):495–504PubMedCrossRef
62.
Zurück zum Zitat James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP (2010) Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003860.pub3 James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP (2010) Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev. doi:10.​1002/​14651858.​CD003860.​pub3
63.
Zurück zum Zitat Hattangadi JA, Taback N, Neville BA, Harris JR, Punglia RS (2012) Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst 104:29–41PubMedCrossRef Hattangadi JA, Taback N, Neville BA, Harris JR, Punglia RS (2012) Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst 104:29–41PubMedCrossRef
Metadaten
Titel
Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls
verfasst von
D. B. Jeffe
M. Pérez
Y. Liu
K. K. Collins
R. L. Aft
M. Schootman
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2048-y

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.